Abstract
The high prevalence of comorbid mental disorders (CMDs), such as anxiety and depression, in patients with inflammatory bowel disease (IBD) is well documented. The reported bidirectional relationship between the two conditions suggests a crucial role of a gut-brain axis in CMD development in patients with IBD. This study aimed to investigate a complex interplay between gut microbiota and host genetic variants relevant to the development of CMDs in IBD. Genome-wide variant data, gut metagenomic data, and/or anxiety/depression estimates were obtained from 507 patients with IBD and 75 healthy controls. A series of integrative analyses were performed, profiling gut microbial diversity, microbial abundance, polygenic risk score, microbial quantitative trait locus (mbQTL), and microbial IBD-risk score. Patients with IBD had significantly lower gut microbial alpha diversity than controls, particularly those with CMD. Beta diversity revealed that a large fraction of IBD-associated taxa contributing to the top principal component were potentially associated with CMD risk. We identified 146 significantly differentially abundant taxa (DATs) between IBD patients and controls, and 48 DATs between CMD-free and CMD-affected IBD patients, with the majority showing consistent changes in abundance between IBD and CMD. Microbial IBD-risk scores, developed to estimate the degree of microbial IBD-specific burden in each individual, supported a significant enrichment of IBD-risk signatures in CMD-affected patients. Additionally, we found an IBD-risk mbQTL for an IBD/CMD-associated DAT, implicating an interplay between IBD-risk variants and gut dysbiosis in the development of both IBD and CMD. Collectively, IBD-associated gut dysbiosis predominantly confers risk of CMD in IBD patients partially through genetic variant-mediated regulation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI23C0661) and the Medical Research Center Program through the National Research Foundation (NRF) of Korea, funded by the Ministry of Science and ICT (NRF-2017R1A5A2014768).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Kyung Hee University hospital gave ethical approval for this work (approval No. KHUH 2018-03-006).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Authors share co-first authorship.
Conflicts of interest The authors disclose no conflicts.
Data availability
All data relevant to the study are included in the article or uploaded as supplementary information. The other data are available from the corresponding authors upon reasonable request.
Abbreviations used in this paper
- ASV
- amplicon sequence variant
- BMI
- body mass index
- CD
- Crohn’s disease
- CI
- confidence intervals
- CMD
- comorbid mental disorders
- DAT
- differentially abundant taxon
- GWAS
- genome-wide association study
- HADS
- hospital anxiety and depression scale
- HBI
- Harvey-Bradshaw index
- IBD
- inflammatory bowel disease
- LD
- linkage disequilibrium
- mbQTL
- microbial quantitative trait locus
- MRS
- microbial risk score
- PC
- principal component
- PCoA
- principal coordinate analysis
- PD
- phylogenetic diversity
- PMS
- partial Mayo score
- PRS
- polygenic risk score
- SNP
- single nucleotide polymorphism
- UC
- ulcerative colitis
- 1KGP3
- 1000 Genomes Project phase 3
